INTRODUCTION {#s0}
============

Antibiotics are weapons of choice in the fight against infectious bacterial diseases to eliminate the causative pathogens or to slow their growth such that host defense mechanisms can clear the infection from the host ([@B1]). Antibiotic exposure triggers a bacterial adaptive response to offset the consequences of the exposure to the given antibiotic. The adaptive response generated to overcome the given stress in a bacterial cell for its better survival and increased fitness is termed the bacterial stress response ([@B2]). Bacteria respond to such changes by altering their gene expression pattern, which helps in adjusting the cellular physiology and metabolism to accommodate the new condition(s), thereby protecting the bacteria against cell damage or death ([@B2]). Different groups of antibiotics target diverse and seemingly unrelated subcellular bacterial targets, thereby generating an unambiguous adaptive stress response ([@B3]) with a signature of the specific antibiotic class; e.g., exposure of *Escherichia coli* cells to fluoroquinolone, aminoglycoside, and β-lactam leads to the generation of SOS ([@B4]), heat shock ([@B5]), and cell envelope ([@B6]) stress responses, respectively.

In light of the antibiotic discovery pipeline running dry along with the looming threat of the advent of a postantibiotic era due to rapid emergence and spread of multidrug-resistant (MDR) pathogens ([@B7]), it is incumbent upon us to safeguard the utility of the currently available chemotherapeutic antibiotics. Consequently, knowledge about molecular mechanisms of antibiotic action, related bacterial responses, factors modulating their activity, and antibiotic resistance could help us in understanding the conditions where resistance is selected and persists. This knowledge could be useful for development of improved antibacterial substances and therapeutic regimens to help us in keeping pace with the remarkable adaptability of pathogenic bacteria.

We have previously shown that supplementation of exogenous glutathione (GSH) in *E. coli* reverses the effect of ciprofloxacin by neutralizing the oxidative stress involved in its antibacterial action ([@B8]). We further established recently that GSH supplementation promotes ciprofloxacin resistance by increasing its efflux from *E. coli* ([@B9]). Therefore, GSH-mediated abrogation of ciprofloxacin-induced bacterial killing can be attributed to both (i) decreased oxidative stress and (ii) increased antibiotic efflux from *E. coli* as shown in [Fig. 1](#fig1){ref-type="fig"}. Since GSH was found to influence more than one biological process here, we were curious to understand the effect of GSH supplementation at the system level as well as in context with the phenotype mentioned above for *E. coli*. Consequently, genome-level *E. coli* expression changes in response to GSH supplementation, subinhibitory ciprofloxacin exposure, and GSH-mediated abrogation of bacterial killing by ciprofloxacin were analyzed. Notably, genome-wide expression changes in antibiotic-resistant *E. coli* have not been adequately explored, with the exception of a previous study using a clinical isolate ([@B10]). Moreover, the genome-level expression changes in bacteria with respect to different types of triggers leading to antibiotic resistance are still unknown. In the present study, we conducted genomic expression profiling of *E. coli* MG1655 with GSH and/or ciprofloxacin using DNA microarrays. The data highlight an interplay of multiple underlying stress response pathways under conditions of exposure of *E. coli* cells to GSH and/or ciprofloxacin. The DNA microarray results were further validated for all the genes (*n* = 40) showing a ≥5.0-fold change in expression using reverse transcription-quantitative PCR (RT-qPCR). In addition, we determined the functional significance of all the above-mentioned genes with respect to the GSH-mediated phenotype by monitoring the effect of different *E. coli* gene deletion mutants on their growth profiles in the presence of GSH and/or ciprofloxacin. Since our transcriptomic data suggested that GSH supplementation promotes the expression of acid shock genes, we also analyzed the effect of exogenous GSH on acid stress adaptation of *E. coli* cells in the present study.

![A schematic diagram showing the effect of glutathione supplementation and the role of previously reported metabolic pathways to counter the antibacterial effect of ciprofloxacin in wild-type and TolC-AcrAB mutant strains of *Escherichia coli*.](sys0011621820001){#fig1}

RESULTS {#s1}
=======

Genome-scale transcriptomic data for *E. coli* MG1655 in response to exogenous GSH and/or ciprofloxacin. {#s1.1}
--------------------------------------------------------------------------------------------------------

We first examined the genome-level expression changes in *E. coli* strains subjected to sub-MIC ciprofloxacin exposure, GSH supplementation, and GSH-mediated abrogation of bacterial killing caused by ciprofloxacin. Accordingly, 4 different groups of growing MG1655 cells, including (i) a control group, (ii) a group exposed to 10 mM GSH, (iii) a group exposed to 3 ng/ml ciprofloxacin, and (iii) a group exposed to 10 mM GSH and 50 ng/ml ciprofloxacin, were subjected to microarray analysis as described in Materials and Methods. The details of the microarray data can be retrieved from the NCBI Gene Expression Omnibus (GEO) database ([GSE93896](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93896)). A heat map of the microarray expression data is shown in [Fig. 2A](#fig2){ref-type="fig"}. Data analysis was based on 5 different types of comparisons, including (i) control versus GSH, (ii) control versus ciprofloxacin (iii), control versus GSH plus ciprofloxacin, (iv) ciprofloxacin versus GSH plus ciprofloxacin, and (v) GSH versus GSH plus ciprofloxacin. To start with, the total number of probe sets detected for the experiment was 10,208, which became 7,603 after the data preprocessing and normalization steps. A total of 1,760 gene/probe sets among the 7,603 were found to be differentially expressed (significant at *P* = ≤0.05). Finally, 609 genes were found to exhibit a ≥2.0-fold change in one of the comparisons defined above (see Table S1 at <http://www.barc.gov.in/publications/mSystems00001-18/>). An inverse relationship between the fold change value and the number of genes affected was evident from the pie chart shown in [Fig. 2B](#fig2){ref-type="fig"}. The similarities and differences in the gene expression patterns seen under 3 different exposure conditions have been depicted in the form of a Venn diagram in [Fig. 2C](#fig2){ref-type="fig"} for all the genes showing a ≥2.0-fold change in expression.

![(A) Heat map of microarray gene expression. Comparisons of gene expression patterns of the whole transcriptome of MG1655 under 4 different exposure conditions are shown. The gradient is representative of the expression differences between the samples, where red indicates upregulated expression of the given gene and blue indicates downregulated expression. Exposure conditions are shown at the top of the figure. (B) Pie chart showing the relationship between the fold change value and the number of genes for 609 genes showing a ≥2.0-fold change in microarray analysis. (C) Venn diagram of the number of genes with ≥2.0-fold differential expression during GSH and/or ciprofloxacin exposure at concentrations of 10 mM GSH, 3 ng/ml (subinhibitory concentration) of ciprofloxacin, and 10 mM GSH with 50 ng of ciprofloxacin/ml (inhibitory concentration). Numbers of upregulated and downregulated genes are indicated next to ↑ and ↓ arrows, respectively.](sys0011621820002){#fig2}

Hierarchical clustering by function of gene product performed using gene ontology analysis of differentially expressed genes (DEG) revealed that biological, cellular, and molecular functions of *E. coli* are affected by the exposure conditions mentioned above. The group of genes affected by GSH exposure comprised those corresponding to redox functions (e.g., *adhE*, *azoR*, *fecA*, *frdB*, and *yeiH*), acid shock (e.g., *asr*, *ogrK*, *ydeO*, and *yegR*), transport (e.g., *lamB emrK*, *srlB*, and *yebF*), and virulence functions (*emrK*, *nmpC*, *yebF*, and *ypdI*) ([Table 1](#tab1){ref-type="table"}). Ciprofloxacin exposure led to increased expression of repair/recombination and cytokinesis genes (e.g., *lexA*, *recA*, *recN*, *dinB*, and *sulA*) ([Table 1](#tab1){ref-type="table"}). On the other hand, the microarray gene expression pattern for the GSH-plus-ciprofloxacin group showed that the levels of expression were largely moderate (with the exception of a few genes) compared to the results from both the GSH and ciprofloxacin groups ([Table 1](#tab1){ref-type="table"}). Among the five comparison groups mentioned above, expression of a total of 41 MG1655 genes was found to be induced or repressed ≥5.0-fold during microarray expression analysis ([Table 1](#tab1){ref-type="table"}).

###### 

Change in expression of 41 genes compared to LB (control condition) detected by microarray analysis[^a^](#ngtab1.1){ref-type="table-fn"}

  Gene name   Avg fold change in expression compared to the control under given exposure condition   Cellular location of the affected gene per the Ecocyc database ([@B47])               
  ----------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------- -----------------------------------
  *adhE*      **4.3↓**                                                                               1.5↑                                                                      **5.9↓**    Cytosol, membrane
  *asr*       9.5↑                                                                                   **1.6↓**                                                                  7.2↑        Periplasmic location
  *azoR*      **12.6↓**                                                                              **1.2↓**                                                                  **9.6↓**    Cytosol
  *csrB*      **5.9↓**                                                                               1.8↑                                                                      **4.9↓**    Cytosol
  *dinB*      1.01↑                                                                                  5.7↑                                                                      2.3↑        Cytosol
  *emrK*      3.8↑                                                                                   **1.4↓**                                                                  3.5↑        Inner membrane
  *fbaA*      **2.4↓**                                                                               2.09↑                                                                     **2.02↓**   Inner membrane
  *ffs*       **1.9↓**                                                                               **6.6↓**                                                                  **1.5↓**    Cytosol
  *fecA*      **4.9↓**                                                                               1.04↑                                                                     **3.7↓**    Outer membrane
  *fimH*      1.4↑                                                                                   **2.9↓**                                                                  1.7↑        Extracellular space, pilus
  *frc*       **3↓**                                                                                 1.4↑                                                                      **3.7↓**    Cytosol
  *frdB*      **3↓**                                                                                 1.5↑                                                                      **3.6↓**    Inner membrane, cytosol
  *gcvP*      **3.4↓**                                                                               1.5↑                                                                      **3.06↓**   Cytosol
  *glpC*      4.6↑                                                                                   **1.3↓**                                                                  5.3↑        Cytosol, inner membrane
  *lamB*      **3.1↓**                                                                               1.4↑                                                                      **5.4↓**    Outer membrane
  *lexA*      **1.5↓**                                                                               4.4↑                                                                      2.3↑        Cytosol
  *manX*      **1.9↓**                                                                               1.7↑                                                                      **3.3↓**    Inner membrane, cytosol
  *manY*      **2.2↓**                                                                               1.6↑                                                                      **4.2↓**    Inner membrane
  *manZ*      **2.8↓**                                                                               1.1↑                                                                      **5.6↓**    Inner membrane
  *nmpC*      **3.2↓**                                                                               1.5↑                                                                      **6.8↓**    Inner membrane
  *ogrK*      6.6↑                                                                                   2.1↑                                                                      8.2↑        Cytosol
  *oxc*       5.7↑                                                                                   **1.1↓**                                                                  3.4↑        Not reported
  *recA*      **1.4↓**                                                                               7.5↑                                                                      3.3↑        Cytosol
  *recN*      **1.1↓**                                                                               11.8↑                                                                     3.6↑        Cytosol
  *srlB*      **2.1↓**                                                                               1.6↑                                                                      **3.6↓**    Cytosol
  *srlD*      **1.2↓**                                                                               3.2↑                                                                      **1.5↓**    Cytosol
  *srlE*      **1.6↓**                                                                               3.9↑                                                                      **2.2↓**    Inner membrane
  *srlR*      **1.01↓**                                                                              4.01**↑**                                                                 **1.3↓**    Cytosol
  *sulA*      **1.3↓**                                                                               7.1↑                                                                      3.5↑        Inner membrane
  *tdcD*      **1.5↓**                                                                               **2.1↓**                                                                  **2.4↓**    Cytosol
  *tnaA*      **2.2↓**                                                                               2.1↑                                                                      **2.4↓**    Cytosol, membrane
  *treC*      **4.2↓**                                                                               1.7↑                                                                      **3.6↓**    Cytosol
  *ybiJ*      **5.8↓**                                                                               1.4↑                                                                      **5.1↓**    Periplasmic space
  *ydeO*      5.3↑                                                                                   **1.3↓**                                                                  **5.5↓**    Cytosol
  *yebF*      1.02↑                                                                                  5.2↑                                                                      4.1↑        Periplasmic space
  *yegR*      11.9↑                                                                                  **1.8↓**                                                                  11.7↑       Not reported
  *yeiH*      4.4↑                                                                                   1.08↑                                                                     6.8↑        Inner membrane
  *yfdX*      9.8↑                                                                                   **1.2↓**                                                                  10.9↑       Periplasmic space
  *yhaK*      **5.8↓**                                                                               **1.03↓**                                                                 **7↓**      Cytosol
  *yjiY*      **6.8↓**                                                                               **1.5↓**                                                                  **7.8↓**    Inner membrane
  *ypdI*      5.5↑                                                                                   1.5↑                                                                      5.9↑        Periplasmic space/ Inner membrane

Font in lightface with an upward arrow represents upregulation, and font in boldface with a downward arrow represents downregulation of the given gene product.

Multigene validation of transcriptomic data using RT-qPCR. {#s1.2}
----------------------------------------------------------

Except for the *ffs* gene (which was too small for optimum primer designing), all 41 of the genes showing ≥5.0-fold-altered expression in microarray analysis were selected for confirmation of the whole-genome transcriptomic data (see [Table 2](#tab2){ref-type="table"} for details) using the RT-qPCR approach. The RT-qPCR expression profile corroborated the microarray results, as the data from 15 of 40 genes fully supported the microarray data in terms of induction or repression pattern for all 3 exposure conditions. Among the remaining 25 genes, an initial ≥2.0-fold cutoff value for microarray data resulted in a perfect match with the qPCR data under all 3 exposure conditions for 13 more genes. Generally, the magnitudes of change in gene expression were found to be different upon comparison of the microarray data with the qPCR data, though the trends largely matched for the two techniques; e.g., the levels of GSH-mediated repression of *nmpC* and *lamB* were found to \~3.2-fold and \~3.1-fold using the microarray and \~6.25-fold and \~10.6-fold using qPCR. The biggest differences in the fold change values were noted for *asr*, whose expression was found to be induced by \~9.5-fold and \~7.2-fold by GSH and GSH plus ciprofloxacin, respectively, by microarray analysis and \~9,000-fold and \~2,600-fold by qPCR analysis. The *asr* repression values after ciprofloxacin exposure were \~1.6 and \~8.3 based on the microarray and qPCR data, respectively. Partial matches or no matches between microarray and qPCR data in terms of expression patterns were observed for remaining 12 genes (including *azoR*, *emrK*, *glpC*, *manY*, *manZ*, *ogrK*, *oxc*, *ybiJ*, *ydeO*, *yegR*, *yfdX*, and *yjiY*). Moreover, it was evident from the data presented in [Fig. 3](#fig3){ref-type="fig"} that the RT-qPCR data for many of the genes showed similar expression profiles for GSH and GSH plus ciprofloxacin, which contrasted with the results seen with *E. coli* cells exposed to ciprofloxacin.

###### 

List of *E. coli* MG1655 genes used for expression analysis using RT-qPCR[^a^](#ngtab2.1){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------------------
  Serial\   Gene\           Gene function                               NCBI\     5′ primer               3′ primer              Amplicon\
  no.       name(s)                                                     gene ID                                                  size (bp)
  --------- --------------- ------------------------------------------- --------- ----------------------- ---------------------- -----------
  1         *acpD*/*azoR*   Thiol stress protection                     947569    GCACTCCGCTGATGAAAT      GGTGCCGCAATAACGATAA    189

  2         *adhE*          Alcohol dehydrogenation                     945837    GGGTTCCCAGTTCCATATTC    GTCGGCAATTTCAGCATAAC   154

  3         *asr*           Acid shock resistance                       945103    TGCTATGGGTCTGTCTTCT     GGGCTTTCTGTTCAGCTT     188

  4         *csrB*          Carbon storage regulation                   2847719   CCAGGATGGAGAATGAGAAC    GCAGCATTCCAGCTACTT     190

  5         *dinB*          Adaptive mutation induction                 944922    CGCCTCCGACATGAATAA      GCATCACCAGATCACACTT    179

  6         *emrK*          Multidrug efflux transportation             946840    TTAAACCGTCAGCCACAAG     CGGTACGACAGCCATTAAC    168

  7         *fba*/*fbaA*    Glycolysis aldol condensation catalyzing    947415    GCCGGAAGACGTTGATTAC     CGGCAGGTTGTGTTTCTT     172

  8         *fecA*          Ferric citrate uptake for porin formation   946427    CGTACAGTACAGCCAGATTG    GGTTGGAGTCGTACTGATTG   158

  9         *fimH*          Receptor recognition and fimbrial\          948847    CTTATGGCGGCGTGTTAT      GCTCACAGGCGTCAAATA     152
                            adhesion                                                                                             

  10        *frdB*          Iron-sulfur fumarate reduction              948666    GCGAAGTATCACCAGTTCTC    GCCATACGCTCCTTCTTAC    161

  11        *gcvP*          Glycine decarboxylation                     947394    GCGCAACAGCAAGAAATG      GTAACCCATGCCGATGTAAG   198

  12        *glpC*          Anaerobic glycerol-3-phosphate\             946735    ACCAGGTCGCTTTCTTTC      CCTGTTTGCGTGCTTTATC    174
                            dehydrogenation                                                                                      

  13        *lamB*          Maltose diffusion facilitation              948548    ATGCACGTTCCGGTATTG      AGCTCTTATCGCCCTCTT     156

  14        *lexA*          Transcriptional repression of\              948544    CTCATCCGTGATCACATCAG    GCAACCCTTCTTCCTCTTC    190
                            SOS regulon                                                                                          

  15        *manX*          2-Deoxyglucose phosphorylation              946334    CGTGCTGTTTCTCGTTGATA    TCACGGCCTGTTTCTACT     189

  16        *manY*          Mannose PTS permease formation              946332    GTTTCACCGTCCGCTAAT      CTCTGATGACCTGCGATAAC   189

  17        *manZ*          Mannose PTS permease formation              946342    CTGGTTGTCTCTCGCATTAC    CGATACCGATGACGAAGAAG   181

  18        *mdoG*/*opgG*   Membrane-derived oligosaccharide\           945005    GTGGATGTGCAGTCGAAA      CATTACCGGCATGGATAGAG   163
                            synthesis                                                                                            

  19        *nmpC*          Outer membrane porin formation              946786    ACTACGGCTCCATCGATTA     CCATCAACCAGACCAAAGAA   178

  20        *ogrK*          Bacteriophage P2 late transcription\        945404    CAAGCCGCTATATCACTGAC    TAATTTGCTGCCCTGACG     165
                            control                                                                                              

  21        *oxc*           Oxalate-induced acid tolerance response     946845    CCGGTGACGATCGTTATTT     CTGTCGTGGTGACGTTATAG   163

  22        *recA*          SOS response regulation                     947170    GGTACAGCTACAAAGGTGAG    GCCTTCGCTATCATCTACAG   164

  23        *recN*          Recombination and DNA repair                947105    CGATCCCAACCGACTATTTG    GTGCCTGCTGATGATGTT     194

  24        *srlB*          Sorbitol permeation                         948971    CCAGATGCTCATCACCTTTC    GTTCGCGAAGGTTGTCTT     176

  25        *srlD*          Sorbitol-6-phosphate dehydrogenase          948937    CCTTTATCAGCGACTTCCAG    CTGTAGCCAGAGTTGTGTTT   181

  26        *srlE*          Sorbitol permeation                         948933    CGTGACTATGACACCAGTAAG   CCGAGACGAATGCCATAAA    163

  27        *srlR*          Sorbitol repression                         948942    CTGCTCTCGCGCTTTAAT      GTCGGTGCCCATAAACAA     198

  28        *sulA*          Stress-Induced mutagenesis\                 947335    TGGGCTACCCTTAACGAA      GCTTACCGGACGCATAATAA   205
                            response promotion                                                                                   

  29        *tdcD*          Propionate and acetate kinase               947635    CAGCGTACGGGTTCATTT      CACCACTTTACCGTCGATAC   159

  30        *tnaA*          [l]{.smallcaps}-Tryptophan cleavage         948221    CGATATTCCGGTGGTAATGG    GCACCATCGCATCTTTCT     164

  31        *treC*          Trehalose-6-phosphate hydrolase             948762    CCCTGTATTGTGGTGCTATC    GTTGTGGTGAGGCTTCTT     152

  32        *ybiJ*          Putative motility and biofilm\              945433    CCAGGCACAGAACATGAATA    CCGCAGTACCGCTTAATTT    155
                            formation factor                                                                                     

  33        *ydeO*          Acid shock resistance                       945922    GCGTAGAAGGTTCAGTCAAT    CATCGTGTTGCCCGTATT     211

  34        *yebF*          Outer membrane porin formation              946363    CGTTGGGCAGATGATCAAA     GCTGATATTCCGCCATTCC    178

  35        *yegR*          Hypothetical function                       946613    TCAGCGTAAACTCGATAACC    TCCTACACCTTCTGTCTTCA   163

  36        *yeiH*          Inner membrane formation                    946668    AAGCGGAAGCCAGTAAAG      CACTTCGTGCACAGTAGAA    155

  37        *yfdW*/*frc*    Oxalate-induced acid tolerance              946842    CGGAAGGCAAAGAGGTAATG    AGGCGAACACTCATCAAAC    167

  38        *yfdx*          Acid shock resistance                       949108    ACGATGGTCACAGCAATTC     CGTCACGCATCGCATATAA    157

  39        *yhaK*          Chlorine binding and oxidative\             947620    CATATCGTGCTCGACAAAGG    GGCAACCAGCGTAATGTT     174
                            stress sensing                                                                                       

  40        *yjiY*          Putative peptide transporter                948914    ATGAAGCGCACCCAATAC      GGTCAGTACCGTTAGCAATC   166

  41        *ypdI*          Colonic acid synthesis                      949107    TTTCCATTTCGGGTGGTG      GGCATTTCTTCTGTGAGGT    157
  ------------------------------------------------------------------------------------------------------------------------------------------

The *ffs* gene encoding a 4.5S RNA component of the signal recognition particle (SRP) is missing from this list as its size was a mere 114 bp, which was difficult to incorporate in the current scheme of RT-qPCR methodology. The gene named *mdoG* (mentioned at serial no. 18 in this table) was used as the reference gene for data analysis purposes using the Livak method ([@B46]). ID, identifier; PTS, phosphotransferase system.

![Changes in gene expression level of 40 genes of MG1655 on exposure to GSH and/or ciprofloxacin by RT-qPCR analysis. The 40 genes are the same as those which exhibited ≥5.0-fold-altered expression in microarray analysis. Mid-logarithmic-phase bacterial cells were used for RT-qPCR analysis per the details mentioned in Materials and Methods. Data represent expression levels of different genes in the presence of (A) 10 mM GSH, (B) 3 ng of ciprofloxacin/ml, and (C) 10 mM GSH with 30 ng of ciprofloxacin/ml. Each bar represents the ratio of the expression level of that gene in the presence of the given exposure condition to the expression level under the control conditions using *mdoG* as an external reference gene. The bar diagram shown here represents data from three different biological replicates (*n* = 3). Error bars represent ± standard errors of the means (SEM).](sys0011621820003){#fig3}

Functional importance of the genes showing altered expression in response to exogenous GSH and/or ciprofloxacin. {#s1.3}
----------------------------------------------------------------------------------------------------------------

To assess the functional importance of the genes which exhibited ≥5.0-fold-altered expression on exposure to exogenous glutathione and/or ciprofloxacin, 36 different single-gene-deletion *E. coli* mutants were picked from the Keio library ([@B11]) and their growth profiles were analyzed and compared with those of the wild-type BW25113 parent strain under GSH and ciprofloxacin exposure conditions similar to those that were used for the microarray and RT-qPCR experiments. The gene deletion mutants corresponding to the 5 remaining genes, namely, *csrB*, *fba*, *ffs*, *gcvP*, and *lexA*, were not available in the Keio gene deletion library. Of the 36 mutant strains tested in the present study, 12 strains carrying a deletion of a gene (including the *asr*, *fecA*, *manX*, *manY*, *ogrK*, *recA*, *recN*, *srlB*, *srlD*, *srlE*, *yieH*, and *yjiY* genes) exhibited a changed growth profile(s) in the presence of GSH and/or ciprofloxacin compared to wild-type parent strain BW25113. The growth curve data for BW25113 along with 5 of the mutants, namely, the *asr*, *manY*, *recA*, *srlE*, and *yeiH* deletion mutants (strains with notable deviations in their growth profiles), are shown in [Fig. 4](#fig4){ref-type="fig"}. The growth profiles of parent strain BW25113 were not very different under the tested exposure conditions, whereas the strain carrying a *recA* deletion was unable to grow wherever ciprofloxacin was present in the medium (even 3 ng/ml ciprofloxacin prevented growth of the strain). The mutants carrying deletions in *yeiH*, *asr*, and *srlE* exhibited poor growth in the presence of GSH or GSH plus ciprofloxacin. The *manY* deletion strain showed changed growth behavior in the presence of both GSH and ciprofloxacin. Among the remaining 7 strains showing moderately altered growth profiles, the *fecA*, *manX*, *ogrK*, *srlB*, *srlD*, and *yjiY* deletion mutants exhibited lower growth with the GSH sample(s) whereas the *recN* deletion mutant showed diminished growth with the ciprofloxacin samples compared to the BW25113 control strain (see Fig. S1 at <http://www.barc.gov.in/publications/mSystems00001-18/>).

![Growth kinetics of *recA*, *yeiH*, *asr*, *srlE*, and *manY* deletion strains compared to wild-type parent *E. coli* BW25113. Shown are the growth curves generated for strains BW25113, JW2669, JW2145, JW5826, JW5430, and JW1807 in LB (control); LB supplemented with 10 mM GSH (GSH); LB with 3 ng of ciprofloxacin/ml (Cip); and LB supplemented with 10 mM GSH and 50 ng of ciprofloxacin/ml (GSH+Cip).](sys0011621820004){#fig4}

Glutathione supplementation leads to increased survival of *E. coli* under acidic conditions. {#s1.4}
---------------------------------------------------------------------------------------------

The exposure to GSH affected different classes of genes, including those corresponding to redox functions, transport, virulence, acid stress, and unknown functions. Though GSH is known to affect most of the biological processes mentioned above either directly or indirectly ([@B12]), acid stress adaptation vis-à-vis GSH supplementation had not been shown previously for *E. coli*. Since GSH significantly altered the expression of acid stress genes of *E. coli*, *viz.*, *asr*, *frc*, *oxc*, *ydeO*, and *yegR*, we investigated whether GSH supplementation promotes the survival of *E. coli* under acidic conditions. Survival of MG1655 at pH 3.0 was measured using the corresponding GSH and ciprofloxacin concentrations at the time of bacterial growth. In the case of the control culture, approximately \~0.05% of the initial bacterial population survived after the acid shock ([Fig. 5](#fig5){ref-type="fig"}), a level that was comparable to the survival seen with ciprofloxacin alone. On the other hand, significantly higher bacterial survival was observed in groups which were supplemented with either GSH (\~0.11%) or a GSH-ciprofloxacin combination (\~0.12%). The data therefore clearly signify that GSH supplementation provides a survival advantage for *E. coli* cells under conditions of an acidic environment.

![Acid resistance of MG1655 with GSH and/or ciprofloxacin at a concentration of 10 mM GSH, 3 ng of ciprofloxacin/ml (subinhibitory concentration), and 10 mM GSH with 50 ng of ciprofloxacin/ml (inhibitory concentration). Bacterial cells were grown to mid-log phase in LB broth (pH 7.0). Cells grown under the exposure conditions mentioned above were diluted 40-fold into LB broth (pH 3.0) and were incubated for 1 h at 37°C. Percent survival data represent ratios of counts of viable cells remaining after acid treatment to the viable counts before treatment. Initial cell densities (before exposure to the acidified medium) ranged from 4 × 10^7^ to 2 × 10^8^ CFU/ml. The results shown are averages from three independent experiments, with the SEMs indicated.](sys0011621820005){#fig5}

DISCUSSION {#s2}
==========

Earlier studies at our laboratory established that GSH decreases the antibacterial effect of ciprofloxacin by neutralizing antibiotic-associated oxidative stress and by promoting antibiotic efflux from *E. coli* cells ([@B8], [@B9]). Here we report *E. coli* genome-level expression changes in the presence of exogenous GSH *per se* and how the bacterial cells conceivably use their molecular networks to offset the effect of the ciprofloxacin by altering their stress response pathways. To the best of our knowledge, this is the first report describing the genome-wide expression changes that occur on exposure to exogenous GSH in *E. coli*. Moreover, our data offer a genomic perspective for GSH-mediated reversal of ciprofloxacin activity in *E. coli* by rationally linking the gene expression changes and functional importance of the genes with an established phenotype reported previously ([@B8]), as GSH is an important modulator of antibiotic activity in bacteria ([@B13]).

Being a prominent cellular antioxidant, GSH has a significant influence on the cellular redox state, thereby upregulating the expression of redox function genes such as *yeiH* and *azoR* in *E. coli* as observed using microarray and RT-qPCR methods. Among the genes mentioned above, *yeiH* has been previously reported to harbor an upstream *sox* box, showing its potential regulation by the *soxRS* system ([@B14]), whereas *azoR* was implicated in thiol-specific stress in a previous study ([@B15]). Genes coding for the Fe citrate transporter (*fecA*) ([@B16]) and for the Fe-S center subunit of fumerate reductase (*frdB*) ([@B17]) are downregulated by GSH, plausibly to avoid the cellular injury that occurs via Fenton reaction-induced ·OH due to elevated cellular Fe^++^ levels. Our results further indicate that GSH could be important for acid stress adaptation of *E. coli* cells. This statement is supported by our transcriptomic data showing that acid stress response genes, namely, *asr*, *frc*, *oxc*, *ydeO*, and *yegR*, are significantly upregulated on exposure to exogenous GSH. Our conclusions are supported by the fact that *asr* has been known to provide a survival advantage for bacteria under acid stress conditions ([@B18]) and the fact that the remaining four genes are critical components of acid resistance networks in bacteria ([@B19], [@B20]) which are regulated by *evgA* of the two-component regulatory system in *Escherichia coli*. Another *evgA*-regulated virulence gene, *emrK*, which has an established role in antibiotic efflux and biofilm formation ([@B21], [@B22]), was upregulated on exposure to GSH. On similar lines, GSH promoted *ypdI* expression, which is important during biofilm formation ([@B23]). GSH-mediated up- and downregulation of *yebF* and *nmpC*, respectively, could be a part of a bacterial strategy to intensify virulence by tolerating higher levels of colicins as this expression pattern has previously been implicated in such phenotypes for *E. coli* ([@B24], [@B25]). Similarly, GSH-mediated repression of *csrB* could contribute to augmenting the bacterial virulence ([@B26]). The results therefore suggest that high GSH levels could promote the overall virulence of *E. coli*, a finding which corroborates our previous animal model data ([@B27]) and is additionally supported by a recent independent report that GSH activates virulence gene expression in the intracellular pathogen *Listeria monocytogenes* ([@B28]). Among the virulence genes affected by GSH supplementation, *emrK* and *yebF* are also involved in transport functions in *E. coli* ([@B22], [@B24]). Likewise, expression of *lamB* and *srlB*, encoding transporters for different sugar derivatives ([@B29], [@B30]), was affected by GSH supplementation. These findings, along with the earlier reports of GSH promoting efflux of antibiotics ([@B9], [@B31]) and potassium ([@B32], [@B33]) from bacteria, imply that GSH is involved in regulating the transport function of *E. coli*. As GSH is known to be an important osmolyte for *E. coli* ([@B12]), repression of *treC* seems reasonable in the light of a previous finding ([@B34]). As per the microarray data, GSH also upregulated the expression of *tnaA*, thus increasing the intracellular levels of indole, which has an important role in antibiotic resistance development in *E. coli* ([@B35]).

Though the presence of GSH is known to be critical for a variety of biological functions, e.g., redox balance, transport, osmotolerance, etc. ([@B12]), its role in acid stress adaptation of *E. coli* is rather underexplored. In the current report, we have shown that GSH provides a survival advantage for *E. coli* under acidic conditions, though its mechanistic details are yet to be understood. Accordingly, it will be interesting to investigate whether GSH-mediated KefB/KefC activation followed by lowering of intracellular pH ([@B32]) contributes to the observed acid resistance phenomenon. Another possibility could be that of increased H~2~S formation in the medium after GSH supplementation, which might affect the pH, as H~2~S is weakly acidic in nature ([@B36]). H~2~S, being a gaseous signaling molecule, could have pleiotropic effects, including oxidative stress and antibiotic susceptibility modulation, inside bacterial cells ([@B37], [@B38]). The glutamic acid-activated acid resistance system ([@B39]) could also be important, as it is an integral constituent of naturally occurring tripeptide GSH.

Exposure of *E. coli* cells to ciprofloxacin at 0.1× the MIC resulted in significant upregulation of repair/recombination and cytokinesis genes, *viz.*, *dinB*, *lexA*, *recA*, *recN*, and *sulA* (the extent of the increase was shown to be ≥4.0-fold using both microarray analysis and RT-qPCR for all genes except *dinB*, which was induced by \>2.0-fold). These data were in complete agreement with earlier reports describing the whole-genome changes ([@B3]) or molecule-level changes ([@B40], [@B41]) seen in response to exposure to fluoroquinolones for *E. coli*. The SOS response after ciprofloxacin exposure in *E. coli* mentioned above can be attributed to DNA damage produced through inhibition of DNA topoisomerase II (DNA gyrase) and topoisomerase IV activities ([@B4], [@B40]). Ciprofloxacin-mediated *yebF* induction in *E. coli* shows that exposure to subinhibitory levels of fluoroquinolone has a similar effect on the expression of this gene, apart from the inhibitory concentrations ([@B3]).

Analysis of transcriptomic data of *E. coli* in response to GSH plus ciprofloxacin revealed that the expression pattern of many genes is in sync with GSH exposure but with a reversal of the trend compared with that seen with the subinhibitory ciprofloxacin exposure (≥2.0-fold change cutoff value using both microarray and RT-qPCR). These abrupt changes in the level of expression offer meaningful insights about a possible mechanism(s) behind the thwarting of the action of ciprofloxacin by GSH to promote antibiotic resistance. For instance, *asr*, *yeiH*, *csrB*, *frdB*, *lamB*, and *treC* are not affected by ciprofloxacin but noteworthy upregulation of *asr* and *yeiH* and downregulation of the remaining genes was observed on exposure to GSH plus ciprofloxacin. On the other hand, the DNA damage response switched on by ciprofloxacin through induction of *recA*, *recN*, and *sulA* ([@B40]) is partially obviated by GSH, confirming its damage-shielding properties as reported previously ([@B42]). The results therefore implicate genes corresponding to redox function (*frdB*, *yeiH*), transport (*lamB*), acid shock (*asr*), DNA damage repair (*recA*, *recN*, and *sulA*), and virulence functions (*csrB*) in GSH-mediated inhibition of ciprofloxacin activity.

Significantly changed growth profiles of one-third (i.e., 12 of 36) of the single-gene-deletion mutants tested in the presence of GSH and/or ciprofloxacin prove the connection with altered expression of the same genes in wild-type parent *E. coli* under analogous exposure conditions. The results further confirm the functional importance of these genes not only at the molecular level but also at the physiological and phenotypic levels. The growth profile of most (10 of 12) of these mutants is compromised (in terms of saturation cell density and/or growth rate) under GSH exposure conditions, suggesting a vital role of these genes in GSH metabolism in *E. coli*. Though GSH is known to affect multiple pathways and networks in bacteria ([@B12], [@B13], [@B28]), a direct link of these genes with GSH adaptation or metabolism had not been reported previously for *E. coli*. The two remaining mutants (*recA* and *dinB*) are known to exhibit increased susceptibility to quinolones in bacteria ([@B43], [@B44]), and our data demonstrate that GSH is not able to mitigate their deficiency to restore the growth profile of *E. coli*. Genes with comparatively low levels of expression changes can sometimes also have an important bearing in terms of physiological effect as seen with the altered growth kinetics of *srlE* and *manY* mutants in the presence of GSH and/or ciprofloxacin ([Fig. 4](#fig4){ref-type="fig"}).

Taken together, the results of our present study reveal that exposure of *E. coli* to ciprofloxacin causes induction of DNA repair and cytokinesis genes. GSH, on the other hand, affects the genes related to redox function, transport, virulence, and acid stress. More than half of the GSH-influenced gene products were localized to a redox-active periplasm or membrane fraction ([Table 1](#tab1){ref-type="table"}), implying that these are the important sites of GSH-mediated changes in *E. coli*. Our results also underscore that response to GSH and/or ciprofloxacin is complex in nature and that one stress pathway cannot be singled out, as multiple cellular responses appear to be directed toward protecting the cell against the given stressor. The type of genes affected raises the possibility that cells surviving exposure to GSH and ciprofloxacin in combination may exhibit increased resistance to other stresses and may be induced to form biofilms. We therefore conclude that GSH supplementation influences the expression of genes corresponding to multiple stress response pathways apart from its diverse physiological roles ([@B12]), including acid resistance (present study) and antibiotic activity reversal ([@B8]) via oxidative stress and efflux modulations in *E. coli* ([@B9]). Consequently, further studies are needed in this direction to understand the network of stress response pathways, including their redundancy, pleiotropy, and cross talk with antibiotic resistance triggers, for efficient management and utilization of antibiotic resources by minimizing the conditions for resistance buildup.

MATERIALS AND METHODS {#s3}
=====================

Bacterial strains and culture conditions. {#s3.1}
-----------------------------------------

Wild-type *E. coli* K-12 strain MG1655 was used for microarray and RT-qPCR analysis. Another wild-type strain, BW25113, and derivatives of that strain carrying single gene deletions ([@B11]) were used to generate their growth profiles. A complete list of the *E. coli* strains used in the present study is given in [Table 3](#tab3){ref-type="table"}. Frozen glycerol stocks of the bacterial cultures were streaked onto Luria-Bertani (LB) agar, and, after overnight growth at 37°C, they were stored at 4°C for short-term storage. Overnight liquid cultures (optical density at 600 nm \[OD~600~\], \~2.0) were inoculated into fresh LB medium (1:100), and the cells were used in mid-exponential phase (OD~600~, \~0.4 to 0.5) for microarray and RT-qPCR analysis.

###### 

List of *E. coli* strains used

  ----------------------------------------------------------------------------------------------------
  Strain name   Genotypic description                                 Source or reference
  ------------- ----------------------------------------------------- --------------------------------
  MG1655        F^−^ λ^−^ *rph-1*                                     Laboratory collection

  BW25113       F^−^ Δ(*araD*-*araB*)*567* Δ*lacZ4787*(::*rrnB-3*)\   National Bio Resource Project\
                λ^−^ *rph-1* Δ(*rhaD*-*rhaB*)*568 hsdR514*            (NBRP), Japan

  JW1228        BW25113 Δ*adhE*::Kan^r^                               Keio collection ([@B11])

  JW5826        BW25113, Δ*asr*::Kan^r^                               Keio collection ([@B11])

  JW1409        BW25113, Δ*azoR*::Kan^r^                              Keio collection ([@B11])

  JW0221        BW25113, Δ*dinB*::Kan^r^                              Keio collection ([@B11])

  JW2365        BW25113, Δ*emrK*::Kan^r^                              Keio collection ([@B11])

  JW4251        BW25113, Δ*fecA*::Kan^r^                              Keio collection ([@B11])

  JW4283        BW25113, Δ*fimH*::Kan^r^                              Keio collection ([@B11])

  JW4114        BW25113, Δ*frdB*::Kan^r^                              Keio collection ([@B11])

  JW2237        BW25113, Δ*glpC*::Kan^r^                              Keio collection ([@B11])

  JW3996        BW25113, Δ*lamB*::Kan^r^                              Keio collection ([@B11])

  JW1806        BW25113, Δ*manX*::Kan^r^                              Keio collection ([@B11])

  JW1807        BW25113, Δ*manY*::Kan^r^                              Keio collection ([@B11])

  JW1808        BW25113, Δ*manZ*::Kan^r^                              Keio collection ([@B11])

  JW5078        BW25113, Δ*nmpC*::Kan^r^                              Keio collection ([@B11])

  JW2067        BW25113, Δ*ogrK*::Kan^r^                              Keio collection ([@B11])

  JW2370        BW25113, Δ*oxc*::Kan^r^                               Keio collection ([@B11])

  JW2669        BW25113, Δ*recA*::Kan^r^                              Keio collection ([@B11])

  JW5416        BW25113, Δ*recN*::Kan^r^                              Keio collection ([@B11])

  JW2673        BW25113, Δ*srlB*::Kan^r^                              Keio collection ([@B11])

  JW2674        BW25113, Δ*srlD*::Kan^r^                              Keio collection ([@B11])

  JW2676        BW25113, Δ*srlR*::Kan^r^                              Keio collection ([@B11])

  JW5430        BW25113, Δ*srlE*::Kan^r^                              Keio collection ([@B11])

  JW0941        BW25113, Δ*sulA*::Kan^r^                              Keio collection ([@B11])

  JW5806        BW25113, Δ*tdcD*::Kan^r^                              Keio collection ([@B11])

  JW3686        BW25113, Δ*tnaA*::Kan^r^                              Keio collection ([@B11])

  JW4198        BW25113, Δ*treC*::Kan^r^                              Keio collection ([@B11])

  JW0787        BW25113, Δ*ybiJ*::Kan^r^                              Keio collection ([@B11])

  JW1494        BW25113, Δ*ydeO*::Kan^r^                              Keio collection ([@B11])

  JW1836        BW25113, Δ*yebF*::Kan^r^                              Keio collection ([@B11])

  JW5837        BW25113, Δ*yegR*::Kan^r^                              Keio collection ([@B11])

  JW2145        BW25113, Δ*yeiH*::Kan^r^                              Keio collection ([@B11])

  JW2371        BW25113, Δ*yfdW*::Kan^r^                              Keio collection ([@B11])

  JW2372        BW25113, Δ*yfdX*::Kan^r^                              Keio collection ([@B11])

  JW3077        BW25113, Δ*yhaK*::Kan^r^                              Keio collection ([@B11])

  JW5791        BW25113, Δ*yjiY*::Kan^r^                              Keio collection ([@B11])

  JW2373        BW25113, Δ*ypdI*::Kan^r^                              Keio collection ([@B11])
  ----------------------------------------------------------------------------------------------------

Glutathione and ciprofloxacin solutions. {#s3.2}
----------------------------------------

A ciprofloxacin stock solution of 2 mg/ml was appropriately diluted using sterile distilled water to adjust the final antibiotic concentration in the growth media. A fresh stock solution (250 mM) of GSH was prepared in sterile distilled water followed by ﬁlter sterilization through a 0.22-μm-pore-size membrane (Millipore) and added to the media prior to use wherever mentioned. When needed, growth medium was supplemented with ciprofloxacin and GSH at the concentrations indicated.

Sample preparation for microarray analysis. {#s3.3}
-------------------------------------------

The microarray-determined mRNA profiles of *E. coli* MG1655 cultures in response to GSH and/or ciprofloxacin were compared with those of control or untreated cultures. Bacterial cells that had been grown overnight were freshly diluted 1:100 in LB medium for collection of total RNA. MG1655 cells were grown under three different conditions, namely, (i) with 10 mM GSH, (ii) with 3 ng/ml ciprofloxacin (subinhibitory antibiotic concentration), and (iii) with 10 mM GSH and 50 ng/ml ciprofloxacin (inhibitory antibiotic concentration). Control cultures were grown in LB with no exogenous GSH or ciprofloxacin added. All the MG1655 cultures mentioned above were collected during mid-logarithmic phase (OD~600~ of 0.4 to 0.5) for microarray analysis. Subsequently, the cells were centrifuged (8,000 × *g*, 5 min, 4°C) and suspended in RNAlater (Qiagen, USA). Two biological replicates were prepared and processed for each of the above-mentioned exposure conditions and controls.

Microarray hybridization and analysis. {#s3.4}
--------------------------------------

Total RNA was obtained using an RNeasy Protect Bacteria minikit (Qiagen) per the manufacturer's instructions. The purity, concentration, and integrity of RNA were confirmed by the use of a Agilent Model 2100 Bioanalyzer and agarose gel electrophoresis. The RNA integrity number for all the samples was ≥7, confirming suitability for the microarray expression experiments. Total RNA was then reverse transcribed, biotin labeled, and purified using a GeneChip IVT express kit. Fragmented, biotinylated cDNA generated using a GeneChip IVT express kit was hybridized to Affymetrix gene chip *E. coli* genome 2.0 arrays for 16 h at 45°C and 60 rpm. Following hybridization, the hybridized probe arrays underwent an automated washing and staining protocol on an automated Affymetrix GeneChip fluidic station and were then scanned on a GeneChip scanner 3000 7G system, where patterns of hybridization were detected. All the steps of microarray hybridization and data preprocessing were performed by an Affymetrix authorized service provider, iLife Discoveries, Gurgaon, India. Raw data sets were extracted from all CEL files (raw intensity files) after scanning of slides. All the original microarray data (CEL files) for control and treated groups were preprocessed using the RMA (Robust Multichip Average) algorithm, which consists of three steps: background adjustment, quantile normalization, and summarization. All of the procedures described above were performed by selecting the RMA algorithm in GeneSpring Gx12.0. Subsequently, genes of low-intensity information content (\>20 percentile) in each data set were filtered out and excluded from the downstream analysis. After this, averages of intensity values were taken for experiment sets for control and treated groups. After the data normalization, including data preprocessing, quality control (principal-component analysis), and baseline transformation steps, differentially expressed genes (DEG) were identified using the criterion that the mean difference in transcript levels was ≥2-fold with a *P* value of \<0.05. Fold change was calculated by comparisons between a given condition (condition 1) and another condition or several other conditions treated as an aggregate (condition 2). Finally, the data set of significantly changed genes was subjected to hierarchical clustering for further functional enrichment using gene ontology (GO) analysis.

Validation of gene expression using reverse transcription-quantitative PCR (RT-qPCR). {#s3.5}
-------------------------------------------------------------------------------------

Selected gene expression results were confirmed using RT-qPCR analysis. *E. coli* strain MG1655 was grown in LB broth in the presence and absence of GSH and ciprofloxacin concentrations similar to those that were used for microarray expression analysis. Mid-log-phase cells of MG1655 (OD~600~, \~0.4 to 0.5) were used for RNA extraction. The RNA was extracted using a NucleoSpin RNA II kit (Macherey-Nagel, Germany) per the manufacturer's instructions. The RNA was further treated with Heat and Run DNase (ArcticZymes, Norway) to remove DNA contamination and quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE). cDNA was synthesized using a qScript cDNA synthesis kit (Quanta Biosciences, USA) and 1.0 μg of RNA in a 20-μl reaction mixture. The qPCR was performed on 3 μl of diluted cDNA (15 ng) using a Kapa SYBR Fast qPCR kit (Kapa Biosystems, USA) and a 0.1 pM concentration of each primer in a 20-μl reaction mixture. The qPCR reactions were prepared using an epMotion 5070 automated PCR Robot (Eppendorf, Germany) in 96-well format. The qPCR run and analysis were performed using a LightCycler 480 system (Roche, USA). The thermocycling conditions included one cycle of denaturation at 95°C for 4 min, followed by 45 cycles of denaturing at 95°C for 2 s and annealing/extension at 60°C for 40 s. The threshold cycle (*C*~*T*~) values were normalized against the previously reported reference gene *mdoG* encoding glucan biosynthesis protein ([@B45]), and the relative gene expression levels were determined using the ΔΔ*C*~*T*~ method ([@B46]). The 41 genes used in the study are listed in [Table 2](#tab2){ref-type="table"} together with their respective functions and the primers used.

Growth profiles of Keio collection single-gene-deletion mutants. {#s3.6}
----------------------------------------------------------------

Growth profiles of GSH-exposed and/or ciprofloxacin-exposed BW25113 and mutant *E. coli* strains lacking genes of interest obtained from the National Institute of Genetics, Mishima, Japan ([@B11]), were generated using a spectrophotometer-based approach. Overnight cultures of different *E. coli* strains were reinoculated (1:100) into a total starting volume of 10 ml LB medium, and 100 µl of these freshly diluted cultures was grown in a honeycomb 100-well plate (Bioscreen; OY Growth Curves, Finland) in a Bioscreen C machine with continuous shaking at 37°C. Absorbance readings were taken every 30 min using a wideband filter. Uninoculated LB broth was used as the control.

Acid resistance assay. {#s3.7}
----------------------

Acid resistance was determined by the method of Masuda and Church ([@B19]), where MG1655 cells were grown to their mid-exponential phase (OD~600~ \~0.3) in the presence and absence of GSH and/or ciprofloxacin, and 50 μl of this cell culture was transferred to 1.95 ml of prewarmed LB medium (adjusted to pH 3.0 with HCl) and incubated at 37°C for 1 h. Viable cells in the acidified culture were counted by plating serial dilutions onto LB agar plates and incubated at 37°C for 16 to 18 h before colony counting was performed. The percentage of survival was the ratio of the counts of viable cells remaining after acid treatment to the viable counts before treatment.

Statistical analysis. {#s3.8}
---------------------

The statistical analysis was performed using GraphPad Prism 7 software (GraphPad Inc., USA) either by one-way analysis of variance (ANOVA) followed by Dunnet's posttest for multiple-group comparisons or a one-tailed unpaired Student's *t* test for two-group comparisons. Asterisks (\*) refer to a *P* value of \<0.05 in comparison to control results. Though the experiments were repeated at least thrice to confirm the reproducibility of the results, the data from a single experiment were used for purposes of representation and analysis of the growth curve data. The number of replicates (*n*) for a given sample is indicated in individual figure legends.
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